Dr Pinder

Editor-in-Chief:  Dr Roger M. Pinder, PhD, DSc.

Dr Pinder is an independent pharma consultant based in the city of York in the UK. He advises and consults worldwide to several pharmaceutical and venture capital organizations. He is also Chairman of the Irish speciality  pharma company NeuroCure Ltd, headquartered in Dublin, and of the New York-based clinical CRO IN-CLINE. He is Founding Editor of Neuropsychiatric Disease and Treatment, the official journal of the International Neuropsychiatric Association (INA). Dr. Pinder is President, and was previously Secretary, of the International Society for Affective Disorders (ISAD). He has also served as Treasurer and Councillor of the International College of Neuropsychopharmacology (CINP).

 

During his industrial career Dr. Pinder held several senior positions in Akzo Nobel, principally with the human pharmaceuticals business unit Organon in both the Netherlands and the USA. He headed global CNS and Cardiovascular R&D for Organon, and was involved in development of the antidepressants mianserin and mirtazapine and the antithrombotics danaparinoid and fondaparinux. He was latterly International Medical Director and Vice-President for Medical Affairs for the CNS and Thrombosis divisions. Dr. Pinder also directed research coordination for the 5 pharmaceutical business units of Akzo Nobel at their headquarters in the Netherlands. Prior to joining Organon, Dr. Pinder was briefly with ADIS Press in New Zealand and earlier spent 7 years working with Roger Brimblecombe at the UK’s Chemical Defence Establishment.

 

Educated in the UK and the USA at the universities of Hull and Virginia, Dr. Pinder holds doctoral degrees in medicinal chemistry (Ph.D.) and neuropsychopharmacology (D.Sc.). He is a fellow of the British Pharmacological Society, the British Association for Psychopharmacology, the European (ECNP) and the International Colleges of Neuropsychopharmacology (CINP), and of ISAD, and serves on the Editorial Board of Medicinal Chemistry Research. His professional research interests include cardiovascular and CNS pharmacology and therapeutics, with a special emphasis on depressive disorders, anti-depressants and the health benefits of wine. He is a regular speaker and chair at international congresses, and has published 5 books and more than 250 review and research articles.

Dr Arciniegas

Associate Editor:  David B. Arciniegas, MD, FANPA, FAPM, CBIST

 

David B. Arciniegas, MD, is Director of the Neurobehavioral Disorders Program at the University of Colorado Denver School of Medicine (UCD-SOM) and Medical Director of the Brain Injury Rehabilitation Unit at HealthONE Spalding Rehabilitation Hospital in Aurora, Colorado. Dr. Arciniegas graduated from the University of Michigan Medical School, and completed his internship in community medicine and residency in psychiatry at UC-SOM. After serving as Chief Resident in the UC-SOM Department of Psychiatry, he undertook concurrent fellowships in Neuroscience Research and Traumatic Brain Injury at the Denver Veterans Affairs Medical Center and in Neuropsychiatry and Clinical Neuroscience Research in the UC-SOM Departments of Psychiatry and Neurology. He subsequently joined the faculty of the UC-SOM, where he now serves as Associate Professor of Psychiatry and Neurology and holds the Michael K. Cooper Professorship in Neurocognitive Disease. Dr. Arciniegas practices as a subspecialist in Behavioral Neurology & Neuropsychiatry, and provides neuropsychiatric consultation and treatment to individuals with recent traumatic brain injuries and other neurological conditions in an acute inpatient neurorehabilitation setting. His research is focused neurobiology and treatment of cognitive impairments, and particularly on the investigation of the cholinergic hypothesis of posttraumatic attention and memory impairments. Dr. Arciniegas receives funding for his research from a variety of federal, state, private, and industry sources, including the National Institutes of Health, Veterans Health Administration, and Centers for Disease Control and Prevention, among others. He has authored or co-authored over 70 articles in refereed journals, 10 book chapters, one textbook, and multiple other articles for professional and lay audiences on the neurobehavioral sequelae of traumatic brain injury and other neurological conditions. He is a frequent lecturer at local, national and international scientific meetings, and an active participant in community and government programs working to improve systems of care for persons with traumatic brain injuries and other neurobehavioral disorders.

Professor Young

Associate Editor (The Americas):  Allan Young MB ChB, MPhil, PhD, FRCPsych

 

Professor Allan Young trained in medicine and psychiatry at the Universities of Edinburgh and Oxford.  He has held academic appointments at the Universities of Edinburgh, Oxford, and Newcastle upon Tyne, latterly holding the Chair of General Psychiatry at Newcastle. Professor Young currently holds the LEEF Endowed Chair in Research in the Department of Psychiatry at the University of British Columbia, Vancouver, Canada, where he is also the Associate Director of the Institute of Mental Health. His research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders. Professor Young has received research grant funding from the UK Medical Research Council, the Wellcome Trust, the Stanley Medical Research Institute, and numerous other funding agencies. He has published widely on the causes and treatment of severe psychiatric illnesses especially mood disorders.